54.65
0.00 (0.00%)
| Penutupan Terdahulu | 54.65 |
| Buka | 54.65 |
| Purata Dagangan (3B) | 2,687,748 |
| Modal Pasaran | 4,499,031,040 |
| Harga / Buku (P/B) | 4.70 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -3.75 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.34% |
| Nisbah Semasa (MRQ) | 16.80 |
| Aliran Tunai Operasi (OCF TTM) | -262.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -177.47 M |
| Pulangan Atas Aset (ROA TTM) | -18.52% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.92% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Akero Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 0.0 |
| Purata | -1.25 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.37% |
| % Dimiliki oleh Institusi | 109.31% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |